ETON
Bearish signalScored 2026-10-11 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
Research, not advice.
À propos
Eton Pharmaceuticals, Inc.
- Nom
- Eton Pharmaceuticals, Inc.
- Secteur
- Healthcare
- Industrie
- Drug Manufacturers - Specialty & Generic
- Bourse
- NASDAQ
- Capitalisation
- $1.4B
- Employés
- 44
- PDG
- Sean E. Brynjelsen
- Site web
- https://www.etonpharma.com
- Marché
- DMACFENCIONSLRMRLXRXPHAR
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 150 000 titres (~8 971 265,44 $ US)
- Insiders
- MAIER PAUL VBRYNJELSEN SEAN
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$2,882,620
Avg sell (VWAP, 90d window) $63.20 vs last close $53.33 (-15.6%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-08-28
- Liquidity
- Liquid $33,517,468/day · 20d vol
- Last synced
-
2026-10-13 21:10:23
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-06 | Krempa David | Sell · S | 4,166 | $55.07 | $229,406 | Form 4 |
| 2026-08-28 | MAIER PAUL V | Sell · S | 128 | $61.77 | $7,907 | Form 4 |
| 2026-08-24 | Krempa David | Sell · S | 25,000 | $65.07 | $1,626,750 | Form 4 |
| 2026-08-20 | BRYNJELSEN SEAN | Sell · S | 7,342 | $62.12 | $456,085 | Form 4 |
| 2026-08-19 | BRYNJELSEN SEAN | Sell · S | 8,978 | $62.65 | $562,472 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2022-10-11 | Thomas Suozzi | Purchase | $15,001 - $50,000 |
Signal
Bearish signalScored 2026-10-11 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
ETON presents a moderate opportunity driven by a genuine earnings catalyst — a 99% product sales growth beat and raised guidance attracting institutional flows from BlackRock — but the investment case is tempered by…
The first sentence of the analysis written for ETON on 2026-10-11 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. 1 purchase disclosure year to date, a thin reading
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Supports a bullish reading. Current ratio 1.57 · operating margin 0.1%
Suggested stop 47.03, nearest stored support minus 0.5 ATR(11.8% under the last close). Reward/risk to the next stored resistance is 1.30. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 53.5% | 60.0% | 66.6% | 67.4% | 88.0% | |
| Ebit Margin | 0.3% | -4.6% | -2.2% | -42.4% | -9.0% | |
| Ebitda Margin | 5.3% | -1.7% | 0.7% | -34.1% | -6.8% | |
| Operating Profit Margin | 0.1% | -6.7% | -3.8% | -38.9% | -6.8% | |
| Pretax Profit Margin | -5.7% | -9.8% | -2.2% | -42.4% | -9.0% | |
| Continuous Operations Profit Margin | -5.8% | -9.8% | -3.0% | -42.4% | -9.0% | |
| Net Profit Margin | -5.8% | -9.8% | -3.0% | -42.4% | -9.0% | |
| Bottom Line Profit Margin | -5.8% | -9.8% | -3.0% | -42.4% | -9.0% | |
| Current Ratio | 1.574 | 2.056 | 1.653 | 3.096 | 5.179 | |
| Quick Ratio | 1.173 | 1.293 | 1.596 | 3.010 | 5.058 | |
| Solvency Ratio | -0.008 | -0.052 | -0.002 | -0.606 | -0.152 | |
| Cash Ratio | 0.674 | 0.749 | 1.317 | 2.524 | 3.161 | |
| Price To Earnings Ratio | -99.471 | -88.800 | -120.000 | -7.833 | -55.284 | |
| Price To Earnings Growth Ratio | -7.460 | -0.286 | 1.335 | -0.022 | 0.587 | |
| Forward Price To Earnings Growth Ratio | -7.460 | -0.286 | 1.335 | -0.022 | 0.587 | |
| Price To Earnings Diluted Ratio | -99.471 | -88.800 | -120.000 | -7.833 | -55.284 | |
| Price To Earnings Diluted Growth Ratio | -7.460 | -0.286 | 1.335 | -0.022 | 0.587 | |
| Price To Book Ratio | 17.398 | 14.120 | 7.258 | 5.422 | 6.134 | |
| Price To Sales Ratio | 5.691 | 8.842 | 3.550 | 3.337 | 4.953 | |
| Price To Free Cash Flow Ratio | 44.649 | 365.770 | 18.597 | 34.880 | -13.551 | |
| Price To Operating Cash Flow Ratio | 43.236 | 355.956 | 16.482 | 14.709 | -22.906 | |
| Debt To Assets Ratio | 0.337 | 0.394 | 0.170 | 0.261 | 0.244 | |
| Debt To Equity Ratio | 1.186 | 1.228 | 0.349 | 0.499 | 0.380 | |
| Debt To Capital Ratio | 0.543 | 0.551 | 0.259 | 0.333 | 0.275 | |
| Long Term Debt To Capital Ratio | 0.454 | 0.550 | 0.000 | 0.292 | 0.230 | |
| Financial Leverage Ratio | 3.522 | 3.116 | 2.051 | 1.914 | 1.558 | |
| Working Capital Turnover Ratio | 3.704 | 2.463 | 2.621 | 1.304 | 1.093 | |
| Operating Cash Flow Ratio | 0.273 | 0.049 | 0.420 | 0.746 | -1.036 | |
| Operating Cash Flow Sales Ratio | 0.132 | 0.025 | 0.215 | 0.227 | -0.216 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.968 | 0.973 | 0.886 | 0.422 | 1.690 | |
| Debt Service Coverage Ratio | 0.311 | -0.323 | -0.005 | -3.645 | -0.607 | |
| Interest Coverage Ratio | 0.015 | -1.295 | -1.125 | -8.649 | -1.435 | |
| Short Term Operating Cash Flow Coverage Ratio | 1.197 | 12.750 | 1.267 | 4.667 | -3.329 | |
| Operating Cash Flow Coverage Ratio | 0.339 | 0.032 | 1.262 | 0.739 | -0.705 | |
| Capital Expenditure Coverage Ratio | 31.604 | 37.269 | 8.794 | 1.729 | -1.449 | |
| Dividend Paid And Capex Coverage Ratio | 31.604 | 37.269 | 8.794 | 1.729 | -1.449 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 107.825 | -547.914 | 454.430 | -8.435 | -67.265 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 53.5% | ▼-6.6% | ▼-13.6% |
| Ebit Margin | 0.3% | ▲4.9% | ▲11.9% |
| Ebitda Margin | 5.3% | ▲7.0% | ▲12.7% |
| Operating Profit Margin | 0.1% | ▲6.8% | ▲11.3% |
| Pretax Profit Margin | -5.7% | ▲4.1% | ▲8.1% |
| Continuous Operations Profit Margin | -5.8% | ▲4.0% | ▲8.2% |
| Net Profit Margin | -5.8% | ▲4.0% | ▲8.2% |
| Bottom Line Profit Margin | -5.8% | ▲4.0% | ▲8.2% |
| Current Ratio | 1.574 | ▼-0.483 | ▼-1.138 |
| Quick Ratio | 1.173 | ▼-0.119 | ▼-1.253 |
| Solvency Ratio | -0.008 | ▲0.043 | ▲0.156 |
| Cash Ratio | 0.674 | ▼-0.075 | ▼-1.011 |
| Price To Earnings Ratio | -99.471 | ▼-10.671 | ▼-25.193 |
| Price To Earnings Growth Ratio | -7.460 | ▼-7.175 | ▼-6.291 |
| Forward Price To Earnings Growth Ratio | -7.460 | ▼-7.175 | ▼-6.291 |
| Price To Earnings Diluted Ratio | -99.471 | ▼-10.671 | ▼-25.193 |
| Price To Earnings Diluted Growth Ratio | -7.460 | ▼-7.175 | ▼-6.291 |
| Price To Book Ratio | 17.398 | ▲3.278 | ▲7.331 |
| Price To Sales Ratio | 5.691 | ▼-3.150 | ▲0.417 |
| Price To Free Cash Flow Ratio | 44.649 | ▼-321.122 | ▼-45.420 |
| Price To Operating Cash Flow Ratio | 43.236 | ▼-312.720 | ▼-38.260 |
| Debt To Assets Ratio | 0.337 | ▼-0.057 | ▲0.056 |
| Debt To Equity Ratio | 1.186 | ▼-0.042 | ▲0.458 |
| Debt To Capital Ratio | 0.542 | ▼-0.009 | ▲0.150 |
| Long Term Debt To Capital Ratio | 0.454 | ▼-0.095 | ▲0.149 |
| Financial Leverage Ratio | 3.522 | ▲0.406 | ▲1.090 |
| Working Capital Turnover Ratio | 3.704 | ▲1.241 | ▲1.467 |
| Operating Cash Flow Ratio | 0.273 | ▲0.225 | ▲0.183 |
| Operating Cash Flow Sales Ratio | 0.132 | ▲0.107 | ▲0.055 |
| Free Cash Flow Operating Cash Flow Ratio | 0.968 | ▼-0.005 | ▼-0.020 |
| Debt Service Coverage Ratio | 0.311 | ▲0.634 | ▲1.165 |
| Interest Coverage Ratio | 0.015 | ▲1.310 | ▲2.513 |
| Short Term Operating Cash Flow Coverage Ratio | 1.197 | ▼-11.553 | ▼-2.113 |
| Operating Cash Flow Coverage Ratio | 0.339 | ▲0.307 | ▲0.006 |
| Capital Expenditure Coverage Ratio | 31.604 | ▼-5.666 | ▲16.014 |
| Dividend Paid And Capex Coverage Ratio | 31.604 | ▼-5.666 | ▲16.014 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 107.825 | ▲655.739 | ▲120.097 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $455.0M | $344.9M | $112.3M | $70.9M | $108.1M | |
| Enterprise value | $460.1M | $360.0M | $96.3M | $61.1M | $100.4M | |
| EV / Sales | 5.75x | 9.23x | 3.04x | 2.88x | 4.60x | |
| EV / Op. cash flow | 43.72x | 371.50x | 14.14x | 12.68x | -21.27x | |
| EV / Free cash flow | 45.15x | 381.74x | 15.95x | 30.07x | -12.59x | |
| EV / EBITDA | 107.83x | -547.91x | 454.43x | -8.44x | -67.27x | |
| Net debt / EBITDA | 1.19x | -22.92x | -75.41x | 1.35x | 5.17x | |
| Current ratio | 1.57x | 2.06x | 1.65x | 3.10x | 5.18x | |
| Income quality | -2.29x | -0.25x | -7.28x | -0.53x | 2.42x | |
| Graham net-net | -$1 | -$1 | $0 | $0 | $0 | |
| Tax burden | 100.9% | 100.4% | 135.8% | 100.0% | 100.0% | |
| Interest burden | -2043.9% | 211.2% | 100.0% | 100.0% | 100.0% | |
| Working capital | $22.1M | $21.1M | $10.6M | $13.5M | $19.0M | |
| Invested capital | $53.6M | $56.2M | $15.5M | $18.6M | $22.9M | |
| Return on assets | -5.0% | -5.0% | -2.9% | -36.0% | -7.1% | |
| Operating ROA | 0.1% | -4.8% | -4.2% | -31.5% | -5.6% | |
| Return on tangible assets | -7.5% | -9.3% | -3.5% | -44.5% | -8.2% | |
| Return on equity | -17.6% | -15.7% | -6.0% | -69.0% | -11.1% | |
| Return on invested capital | 0.1% | -4.6% | -5.7% | -42.1% | -6.1% | |
| Return on capital employed | 0.1% | -4.6% | -7.7% | -44.5% | -6.5% | |
| Earnings yield | -1.0% | -1.1% | -0.8% | -12.7% | -1.8% | |
| Free cash flow yield | 2.2% | 0.3% | 5.4% | 2.9% | -7.4% | |
| Capex / Op. cash flow | 3.2% | 2.7% | 11.4% | 57.8% | -69.0% | |
| Capex / Depreciation | 8.2% | 2.3% | 86.0% | 157.2% | 705.4% | |
| Capex / Sales | 0.4% | 0.1% | 2.4% | 13.1% | 14.9% | |
| SG&A / Sales | 44.8% | 58.3% | 59.8% | 87.4% | 66.3% | |
| R&D / Sales | 9.7% | 8.3% | 10.5% | 18.8% | 28.6% | |
| Stock comp / Sales | 6.9% | 8.1% | 9.9% | 19.8% | 15.5% | |
| Intangibles / Total assets | 33.5% | 45.8% | 14.9% | 19.0% | 13.2% | |
| Days sales outstanding | 54d | 50d | 39d | 32d | 91d | |
| Days payables outstanding | 108d | 97d | 64d | 93d | 247d | |
| Operating cycle | 205d | 407d | 71d | 61d | 168d | |
| Cash conversion cycle | 97d | 309d | 7d | -32d | -79d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-09-02 Connor Clark & Lunn Investment Management Ltd. Makes New $476,000 Investment in Eton Pharmaceuticals, Inc. $ETON Connor Clark and Lunn Investment Management Ltd. purchased a new stake in Eton Pharmaceuticals, Inc. (NASDAQ: ETON) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 13,150 shares of the company''s stock, valued at approximately $476,000. Other large investors have also
- 2026-08-31 BlackRock Inc. Invests $68.63 Million in Eton Pharmaceuticals, Inc. $ETON BlackRock Inc. bought a new position in Eton Pharmaceuticals, Inc. (NASDAQ: ETON) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 1,895,833 shares of the company''s stock, valued at approximately $68,629,000. BlackRock Inc. owned about 6.92% of Eton Pharmaceuticals at the
- 2026-08-30 Eton Pharmaceuticals, Inc. $ETON Stock Holdings Increased by Bank of America Corp DE Bank of America Corp DE boosted its holdings in shares of Eton Pharmaceuticals, Inc. (NASDAQ: ETON) by 37.8% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 144,367 shares of the company''s stock after purchasing an additional 39,571 shares
- 2026-08-28 Bank of Nova Scotia Acquires New Position in Eton Pharmaceuticals, Inc. $ETON Bank of Nova Scotia acquired a new stake in shares of Eton Pharmaceuticals, Inc. (NASDAQ: ETON) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 17,200 shares of the company''s stock, valued at approximately $623,000. Bank of Nova Scotia owned about
- 2026-08-27 Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference DEER PARK, Ill., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company''s executive leadership team will host 1x1 meetings on September 9, 2026 at the 2026 Wells Fargo Healthcare Conference being held September 8-10, 2026 in Boston, MA.
- 2026-08-14 Why Eton Pharmaceuticals Is Top of the Class Today Eton Pharmaceuticals beat on both top and bottom lines last night. Management is licensing a new drug, and raising guidance through the end of 2026.
- 2026-08-14 Eton Pharmaceuticals: No Reason Pharma Can''t Deliver More Great Earnings Like These Eton Pharmaceuticals, Inc. delivered record Q2 2026 results, with product sales up 99% and full-year revenue guidance raised to over $145 million. ETON targets over $500 million in peak annual sales by leveraging organic growth, pipeline development, and strategic acquisitions in rare disease markets. Management expects adjusted EBITDA margins to exceed 35% in 2026, aiming for 50% by 2028, with gross margins rising from 70% to over 75%.
- 2026-08-14 Eton Pharmaceuticals, Inc. (ETON) Q2 2026 Earnings Call Transcript Eton Pharmaceuticals, Inc. (ETON) Q2 2026 Earnings Call Transcript
- 2026-08-13 Eton Pharmaceuticals Q2 Earnings Call Highlights Eton Pharmaceuticals NASDAQ: ETON reported second-quarter revenue nearly doubled from a year earlier, driven by the relaunch of HEMANGEOL and growth across its pediatric endocrinology and rare-disease portfolio. The company raised its full-year revenue and profitability outlook while outlining plans to advance newly acquired and internally developed products.
- 2026-08-13 Eton Pharmaceuticals, Inc. (ETON) Q2 Earnings and Revenues Beat Estimates Eton Pharmaceuticals, Inc. (ETON) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to a loss of $0.1 per share a year ago.